Runsheng Li

This inventor holds 16 USPTO granted patents and 15 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Lanova Medicines Limited, Lanova Medicines Limited Company, Lanova Medicines Development Co., Ltd.. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Runsheng Li. Retrieved from https://idiyas.com/inventor/runsheng-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 15)

% Patents Active = 81.3

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 2 (Patent Applications = 16)

Average Co-Inventor Count = 1.7

ph-index = 2

Forward Citations = 8(Granted Patents)

Company Filing History:

6 out of 7

Lanova Medicines Limited

patents

6 out of 6

Lanova Medicines Limited Company

patents

3 out of 3

Lanova Medicines Development Co., Ltd.

patents

4. 1 out of 1

Lanova Medicines Development Co., Ltd.

patent

Years Active: 2021-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692318 - ANTI-4-1BB NANOBODIES (2026-07-28),

2. 12583925 - BISPECIFIC ANTIBODIES TARGETING PD1 AND VEGF (2026-03-24),

3. 12570742 - ANTI-SIRPalpha MONOCLONAL ANTIBODIES AND USES THEREOF (2026-03-10),

4. 12324936 - Methods of treating cancer by administering an antibody-drug conjugate targeting human claudin 18.2 (2025-06-10),

5. 12291537 - Compounds, compositions and methods (2025-05-06),

6. 12281162 - Chimeric antigen receptors targeting GPRC5D (2025-04-21),

7. 12247081 - CEACAM5-dependent 4-1BB-agonistic bispecific antibodies (2025-03-11),

8. 12215150 - Anti-SLC34A2 monoclonal antibodies and uses thereof (2025-02-04),

9. 12194106 - Antibodies targeting LIV-1 and uses thereof (2025-01-14),

10. 12180276 - Antibodies and antibody-drug conjugates targeting claudin 6 (2024-12-31),

11. 12018076 - Anti-claudin 18.2 antibodies and uses thereof (2024-06-25),

12. 11873342 - Anti-CCR8 monoclonal antibodies and uses thereof (2024-01-16),

13. 11554177 - Antibody-drug conjugates targeting human Claudin 18.2 (2023-01-17),

14. 11485783 - Anti-GPRC5D monoclonal antibodies and uses thereof (2022-11-01),

15. 11098118 - Anti-claudin 18.2 antibodies and uses thereof (2021-08-24),

Title: The Innovative Contributions of Runsheng Li

Introduction

Runsheng Li is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of cancer treatment. With a total of 13 patents to his name, he has made remarkable strides in developing innovative therapies that target specific proteins involved in cancer progression.

Latest Patents

One of his latest patents focuses on methods of treating cancer by administering an antibody-drug conjugate that targets human claudin 18.2. This patent provides detailed information about antibody-drug conjugates that contain a drug moiety attached to an antibody or fragment that specifically binds to the wild-type human claudin 18.2 protein. The binding occurs at the β3-β4 loop and the β5 strand of the CLDN18.2 protein, which is crucial for the development of effective cancer therapies.

Career Highlights

Throughout his career, Runsheng Li has worked with various companies, including Lanova Medicines Limited. His work has been instrumental in advancing the understanding and treatment of cancer through innovative drug development.

Collaborations

Runsheng Li has collaborated with notable colleagues, including Wentao Huang and Ying Qin Zang, to further enhance the research and development of cancer therapies.

Conclusion

Runsheng Li's innovative work in the field of cancer treatment exemplifies the impact of targeted therapies in modern medicine. His contributions continue to pave the way for advancements in cancer research and treatment options.

Profile summary based on public USPTO records.